Patents by Inventor Lianghong Zheng

Lianghong Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190177796
    Abstract: Disclosed herein are methods of increasing the expression rate of epigenetic markers such as ELOVL2, KLF14, and PENK with administration of a therapeutic agent (e.g., vitamin C or its derivatives, analogs, metabolites, prodrugs, or pharmaceutically acceptable salts thereof). Also described herein are methods of modulating the methylation pattern of epigenetic markers such as ELOVL2, KLF14, and PENK with administration of a therapeutic agent (e.g., vitamin C or its derivatives, analogs, metabolites, prodrugs, or pharmaceutically acceptable salts thereof).
    Type: Application
    Filed: November 19, 2018
    Publication date: June 13, 2019
    Inventors: Kang Zhang, Rui Hou, Lianghong Zheng
  • Publication number: 20190136327
    Abstract: Disclosed herein are methods and kits for identifying a subject as having leukemia. Also provided herein are methods and kits for determining a leukemia subtype in subject. Further provided herein are methods and kits for determining the prognosis of a subject having leukemia and for determining the progression of leukemia in a subject.
    Type: Application
    Filed: August 3, 2018
    Publication date: May 9, 2019
    Inventors: Kang ZHANG, Rui HOU, Lianghong ZHENG
  • Publication number: 20190110753
    Abstract: Disclosed herein are systems, methods, devices, and media for carrying out medical diagnosis of ophthalmic diseases and conditions. Deep learning algorithms enable the automated analysis of ophthalmic images to generate predictions of comparable accuracy to clinical experts.
    Type: Application
    Filed: October 15, 2018
    Publication date: April 18, 2019
    Inventors: Kang ZHANG, Rui HOU, Lianghong ZHENG
  • Patent number: 10202650
    Abstract: Disclosed herein are methods of increasing the expression rate of epigenetic markers such as ELOVL2, KLF14, and PENK with administration of a therapeutic agent (e.g., vitamin C or its derivatives, analogs, metabolites, prodrugs, or pharmaceutically acceptable salts thereof). Also described herein are methods of modulating the methylation pattern of epigenetic markers such as ELOVL2, KLF14, and PENK with administration of a therapeutic agent (e.g., vitamin C or its derivatives, analogs, metabolites, prodrugs, or pharmaceutically acceptable salts thereof).
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: February 12, 2019
    Assignees: YOUHEALTH BIOTECH, LIMITED, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Kang Zhang, Rui Hou, Lianghong Zheng
  • Publication number: 20180341745
    Abstract: Disclosed herein are methods, systems, platforms, non-transitory computer-readable medium, services, and kits for determining a cancer type in an individual. Also described herein include methods, systems, platforms, non-transitory computer-readable medium, and compositions for generating a CpG methylation profile database.
    Type: Application
    Filed: January 8, 2018
    Publication date: November 29, 2018
    Inventors: Kang ZHANG, Rui HOU, Lianghong ZHENG
  • Patent number: 10093986
    Abstract: Disclosed herein are methods and kits for identifying a subject as having leukemia. Also provided herein are methods and kits for determining a leukemia subtype in subject. Further provided herein are methods and kits for determining the prognosis of a subject having leukemia and for determining the progression of leukemia in a subject.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: October 9, 2018
    Assignees: YOUHEALTH BIOTECH, LIMITED, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Kang Zhang, Rui Hou, Lianghong Zheng
  • Publication number: 20180274039
    Abstract: Disclosed herein, in certain embodiments, are methods and kits for diagnosing a subject as having hepatocellular carcinoma (HCC) or lung cancer. In some instances, also described herein are methods of determining the prognosis of the subject having HCC or lung cancer. In additional instances, described herein are methods of determining the specific staging of HCC or lung cancer in a subject.
    Type: Application
    Filed: March 2, 2018
    Publication date: September 27, 2018
    Inventors: Kang ZHANG, Rui HOU, Lianghong ZHENG
  • Patent number: 9984201
    Abstract: Disclosed herein are methods, systems, platforms, non-transitory computer-readable medium, services, and kits for determining a cancer type in an individual. Also described herein include methods, systems, platforms, non-transitory computer-readable medium, and compositions for generating a CpG methylation profile database.
    Type: Grant
    Filed: December 31, 2015
    Date of Patent: May 29, 2018
    Assignees: YOUHEALTH BIOTECH, LIMITED, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Kang Zhang, Rui Hou, Lianghong Zheng
  • Publication number: 20180094325
    Abstract: Disclosed herein are methods and kits for identifying a subject as having esophagus cancer, pancreatic cancer, or stomach cancer. Also provided herein are methods and kits for generating the methylation profile of a biomarker associated with esophagus cancer, pancreatic cancer, or stomach cancer.
    Type: Application
    Filed: December 12, 2017
    Publication date: April 5, 2018
    Inventors: Kang ZHANG, Rui HOU, Lianghong ZHENG
  • Publication number: 20180010192
    Abstract: Disclosed herein are methods and kits for identifying a subject as having leukemia. Also provided herein are methods and kits for determining a leukemia subtype in subject. Further provided herein are methods and kits for determining the prognosis of a subject having leukemia and for determining the progression of leukemia in a subject.
    Type: Application
    Filed: February 16, 2017
    Publication date: January 11, 2018
    Inventors: Kang ZHANG, Rui HOU, Lianghong ZHENG
  • Publication number: 20170342496
    Abstract: Disclosed herein are methods of increasing the expression rate of epigenetic markers such as ELOVL2, KLF14, and PENK with administration of a therapeutic agent (e.g., vitamin C or its derivatives, analogs, metabolites, prodrugs, or pharmaceutically acceptable salts thereof). Also described herein are methods of modulating the methylation pattern of epigenetic markers such as ELOVL2, KLF14, and PENK with administration of a therapeutic agent (e.g., vitamin C or its derivatives, analogs, metabolites, prodrugs, or pharmaceutically acceptable salts thereof).
    Type: Application
    Filed: May 31, 2017
    Publication date: November 30, 2017
    Inventors: Kang ZHANG, Rui HOU, Lianghong ZHENG
  • Publication number: 20170072025
    Abstract: Disclosed herein are methods and pharmaceutical compositions for the treatment of glaucoma by interfering with expression of genes, such as p16, in cells of the eye. These methods and compositions employ nucleic acid based therapies.
    Type: Application
    Filed: September 9, 2016
    Publication date: March 16, 2017
    Inventors: Lianghong ZHENG, Jie ZHU, Ling ZHAO, Michael AI, Oulan LI, Kang ZHANG
  • Publication number: 20160210403
    Abstract: Disclosed herein are methods, systems, platforms, non-transitory computer-readable medium, services, and kits for determining a cancer type in an individual. Also described herein include methods, systems, platforms, non-transitory computer-readable medium, and compositions for generating a CpG methylation profile database.
    Type: Application
    Filed: December 31, 2015
    Publication date: July 21, 2016
    Inventors: Kang Zhang, Rui Hon, Lianghong Zheng